ARQT Q2 2024 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+494.6% YoY

Gross Profit

$27M88.8% margin

Operating Income

-$50M-162.3% margin

Net Income

-$52M-169.6% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-37.7%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$45M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$445M

Total Liabilities

$258M

Stockholders' Equity

$186M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$5M	+494.6%
Gross Profit	$27M	$4M	+520.6%
Operating Income	-$50M	-$67M	+25.0%
Net Income	-$52M	-$71M	+26.3%